Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Conditions
Brief summary
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.
Detailed description
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study. ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study. After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.
Interventions
PROCEDUREAcupressure Therapy
Undergo auricular acupressure
OTHERBest Practice
Receive usual care
PROCEDUREBiospecimen Collection
Undergo collection of blood samples
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
National Center for Complementary and Integrative Health (NCCIH)
National Center for Advancing Translational Sciences (NCATS)
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18-65 years of age * Stage II-IV gastric, esophageal, or pancreatic cancer * Appetite score on visual analog scale ≤ 70/100 * At least 60 days of planned systemic treatment, whether already initiated or scheduled to be initiated * Access to phone and electronic device for study contacts and questionnaires * Willing and able to attend 4 in-person auricular acupressure treatments at the Fred Hutch South Lake Union Clinic * Willing and able to perform 4 at-home self-applied treatments of auricular acupressure * Participants must not have received acupressure or acupuncture for low appetite within last 30 days * Participants must not be actively using corticosteroids, mirtazapine (Remeron), olanzapine (Zyprexa), or Marinol for appetite stimulation at baseline * Participants must be able to intake food orally and not require sole or supplemental intravenous nutrition at baseline * Participants must not have a history of physiological eating disorders (e.g., anorexia nervosa) in the last 3 years * Participants must not have a current known or diagnosed immunodeficiency * Participants must have an intact auricular pinna * Able to understand and willing to sign written informed consent in English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retention (feasibility) | Up to 8 weeks | Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit. |
| Intervention fidelity (feasibility) | Up to 8 weeks | Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis. |
| Acceptability (feasibility) | Up to 16 weeks | Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews. |
| Accrual (feasibility) | Up to 15 months | Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period. |
| Intervention adherence (feasibility) | Up to 8 weeks | Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in body weight (kg) | Baseline to week 4 | Analyses will assess change in each outcome as a change from baseline to week 4. |
| Change in appetite | Baseline to week 4 | As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. |
Countries
United States
Contacts
Primary ContactBlake Langley
Outcome results
None listed